Abstract
Bispecific antibodies (BsAbs) have emerged as crucial therapeutic agents for patients with relapsed/refractory diffuse large B-cell lymphoma, multiple myeloma, and most recently, lung cancer. These therapies have demonstrated remarkable efficacy in clinical trials; however, multidisciplinary collaboration is essential to ensure optimal patient outcomes amid the operational complexities associated with BsAb therapy. As BsAbs are being prepared for broader adoption, clinicians and treatment centers must navigate operational challenges, including financial considerations, patient selection, caregiver involvement, and transitions of care. Centers must also be knowledgeable to manage toxicities such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome. We therefore convened a panel of academic and community practice pharmacists with experience using BsAbs in clinical trial and standard-of-care settings to provide comprehensive recommendations with a focus on successful onboarding and operationalization of BsAb therapies.
References
Ahn, M. J., Cho, B. C., Felip, E., Korantzis, I., Ohashi, K., Majem, M.,...Owonikoko, T. K. (2023). Tarlatamab for patients with previously treated small-cell lung cancer. The New England Journal of Medicine, 389(22), 2063–2075. https://doi.org/10.1056/NEJMoa2307980
Atembina, L., Boehmer, L., Terrell, K., Koka, R., Janakiram, M., Grothey, A.,…El Chaer, F. (2021). Multidisciplinary provider insights to promote adoption of bispecific antibodies to treat cancer in the community. Blood, 138(Supplement 1), 4033. https://doi.org/10.1182/blood-2021-153794
Balogh, E. P., Ganz, P. A., Murphy, S. B., Nass, S. J., Ferrell, B. R., & Stovall, E. (2011). Patient-centered cancer treatment planning: Improving the quality of oncology care. Summary of an Institute of Medicine workshop. The Oncologist, 16(12), 1800–1805. https://doi.org/10.1634/theoncologist.2011-0252
Bansal, R., Paludo, J., Corraes, A., Spychalla, M., Haugen, K., Khurana, A.,…Lin, Y. (2023). Outpatient management of CAR-T and teclistamab for patients with lymphoma and multiple myeloma. Blood, 142(Supplement 1), 253. https://doi.org/10.1182/blood-2023-187186
Budde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P.,…Bartlett, N. L. (2022). Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. The Lancet. Oncology, 23(8), 1055–1065. https://doi.org/10.1016/S1470-2045(22)00335-7
Centers for Medicare & Medicaid Services. (2015). Fact sheet: Two-midnight rule. https://www.cms.gov/newsroom/fact-sheets/fact-sheet-two-midnight-rule-0.
Centers for Medicare & Medicaid Services. (2024a). HCPCS - general information.
Centers for Medicare & Medicaid Services. (2024b). New medical services and new technologies. https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/new-medical-services-and-new-technologies.
Centers for Medicare & Medicaid Services. (n.d.-a). CMS web pricer.
Centers for Medicare & Medicaid Services. (n.d.-b). Medicare administrative contractors. https://www.cms.gov/medicare/coding-billing/medicare-administrative-contractors-macs.
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P.,…Krishnan, A. (2022). Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. The New England Journal of Medicine, 387(24), 2232–2244. https://doi.org/10.1056/NEJMoa2204591
Crist, M., Emadi, A., & Duffy, A. (2020). Real-world experience managing blinatumomab toxicities in adults with relapsed/refractory acute lymphoblastic leukemia. Journal of Oncology Pharmacy Practice, 26(5), 1080–1085. https://doi.org/10.1177/1078155219881680
Crombie, J. L., Graff, T., Falchi, L., Karimi, Y. H., Bannerji, R., Nastoupil, L. J.,…Dickinson, M. (2024). Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood, 143(16), 1565–1575. https://doi.org/10.1182/blood.2023022432
Davis, J. A., Dima, D., Ahmed, N., DeJarnette, S., McGuirk, J., Jia, X.,…Hashmi, H. (2024). Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed/refractory multiple myeloma. Transplantation and Cellular Therapy, 30(3), 298–305. https://doi.org/10.1016/j.jtct.2023.12.015
Davis, J. A., Shockley, A., & Hashmi, H. (2022). The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. Journal of Oncology Pharmacy Practice, 28(4), 960–968. https://doi.org/10.1177/10781552211073517
DePadova, S., Howlett, C., & Rivera, K. (2016). A multidisciplinary approach to standardizing processes for blinatumomab administration. Clinical Journal of Oncology Nursing, 20(5), 466–469. https://doi.org/10.1188/16.CJON.466-469
Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G.,…Hutchings, M. (2022). Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. The New England Journal of Medicine, 387(24), 2220–2231. https://doi.org/10.1056/NEJMoa2206913
Dima, D., Davis, J. A., Ahmed, N., Jia, X., Sannareddy, A., Shaikh, H., & Hashmi, H. (2024). Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: A real-world experience. Transplantation and Cellular Therapy, 30(3), 308.e1–308.e13. https://doi.org/10.1016/j.jtct.2023.12.016
Dima, D., Sannareddy, A., Ahmed, N., Davis, J. A., Shaikh, H., Mahmoudjafari, Z., & Abdallah, A.-O. (2023). Toxicity and efficacy outcomes of teclistamab in patients with relapsed-refractory multiple myeloma (RRMM) above the age of 70 years: A multicenter study. Blood, 142(Supplement 1), 3330. https://doi.org/10.1182/blood-2023-180458
Dombret, H., Topp, M. S., Schuh, A. C., Wei, A. H., Durrant, S., Bacon, C. L.,…Kantarjian, H. (2019). Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leukemia & Lymphoma, 60(9), 2214–2222. https://doi.org/10.1080/10428194.2019.1576872
Falchi, L., Vardhana, S. A., & Salles, G. A. (2023). Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities. Blood, 141(5), 467–480. https://doi.org/10.1182/blood.2021011994
Graf, K. C., Davis, J. A., & Cendagorta, A. M. (2024). ‘Fast but not so furious’: A condensed but safe and cost-effective step-up dosing regimen of teclistamab for relapsed refractory multiple myeloma. Transplantation and Cellular Therapy, 30(2), S381.
Granger, K., Gaffney, K. J., & Davis, J. A. (2023). Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. Journal of Oncology Pharmacy Practice, 29(3), 722–726. https://doi.org/10.1177/10781552231154809
Greenbaum, U., Strati, P., Saliba, R. M., Torres, J., Rondon, G., Nieto, Y.,…Ahmed, S. (2021). CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Advances, 5(14), 2799–2806. https://doi.org/10.1182/bloodadvances.2021004575
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., & Turtle, C. J. (2017). Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discovery, 7(12), 1404–1419. https://doi.org/10.1158/2159-8290.CD-17-0698
Janssen Oncology. (2023). Talvey (talquetamab-tgvs) package insert. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/talvey-pi.pdf.
Janssen Oncology. (2024). Tecvayli (teclistamab-cqyv) package insert. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/tecvayli-pi.pdf.
Jim, H. S. L., Quinn, G. P., Barata, A., Cases, M., Cessna, J., Gonzalez, B.,…Pidala, J. (2014). Caregivers’ quality of life after blood and marrow transplantation: A qualitative study. Bone Marrow Transplantation, 49(9), 1234–1236. https://doi.org/10.1038/bmt.2014.118
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M.,…Topp, M. S. (2017). Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. The New England Journal of Medicine, 376(9), 836–847. https://doi.org/10.1056/NEJMoa1609783
Karschnia, P., Arrillaga-Romany, I. C., Eichler, A., Forst, D. A., Gerstner, E., Jordan, J. T.,…Dietrich, J. (2023). Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro-Oncology, 25(12), 2239–2249. https://doi.org/10.1093/neuonc/noad118
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N.,…Neelapu, S. S. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625–638. https://doi.org/10.1016/j.bbmt.2018.12.758
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R.,…Mohty, M. (2023). Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nature Medicine, 29(9), 2259–2267. https://doi.org/10.1038/s41591-023-02528-9
Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J.,…Smith, E. L. (2022). GPRC5D-targeted CAR T cells for myeloma. The New England Journal of Medicine, 387(13), 1196–1206. https://doi.org/10.1056/NEJMoa2209900
Metoyer, L. J. (2013). Education of hematopoietic stem cell transplant caregivers in preparation for their role. Journal of the Advanced Practitioner in Oncology, 4(6), 432–437. https://doi.org/10.6004/jadpro.2013.4.6.6
Mohan, M., Chakraborthy, R., Bal, S., Nellore, A., Baljevic, M., D’Souza, A., & Costa, L. J. (2023). Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. British Journal of Haematology, 203(5), 736–746.
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A.,…Usmani, S. Z. (2022). Teclistamab in relapsed or refractory multiple myeloma. The New England Journal of Medicine, 387(6), 495–505. https://doi.org/10.1056/NEJMoa2203478
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J. F., Butler, M. O., Schlaak, M.,…Gastaud, L. (2021). Overall survival benefit with tebentafusp in metastatic uveal melanoma. The New England Journal of Medicine, 385(13), 1196–1206. https://doi.org/10.1056/NEJMoa2103485
Oranges, K., Windawi, S., Powell, S., Dallago, D., Escobar, N., & Rheingold, S. R. (2020). How we infuse blinatumomab. Pediatric Blood & Cancer, 67(9), e28541. https://doi.org/10.1002/pbc.28541
Pemmaraju, A. A., Stevens, C. A., Yam, N. T., & Daniels, C. E. (2021). Challenges in REMS compliance. American Journal of Health-System Pharmacy, 78(12), 1036–1037. https://doi.org/10.1093/ajhp/zxab075
Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S. P.,…Mateos, M.-V. (2023). Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer Journal, 13(1), 116. https://doi.org/10.1038/s41408-023-00879-7
Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K.,…Chari, A. (2024). GPRC5D as a novel target for the treatment of multiple myeloma: A narrative review. Blood Cancer Journal, 14(1), 24. https://doi.org/10.1038/s41408-023-00966-9
Scott, S. A., Marin, E. M., Maples, K. T., Joseph, N. S., Hofmeister, C. C., Gupta, V. A.,…Nooka, A. K. (2023). Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer Journal, 13(1), 191. https://doi.org/10.1038/s41408-023-00963-y
Sean, R., Maria, C. L., Carra, S. S., Stephanie, P., Thomas, M., Amanda, A., & Abigail, H. (2018). Fit for duty?: Evaluating the physical fitness requirements of battlefield airmen. Rand Health Quarterly, 7(2), 8.
Shank, B. R., Nguyen, P. A. A., & Pherson, E. C. (2017). Transitions of care in patients with cancer. The American Journal of Managed Care, 23(7 Spec No.), SP280–SP284.
Spanjaart, A. M., Pennings, E. R. A., Kos, M., Mutsaers, P. G. N. J., Lugtenburg, P. J., van Meerten, T.,…Kersten, M. J. (2023). Development of a core set of patient- and caregiver-reported signs and symptoms to facilitate early recognition of acute chimeric antigen receptor T-cell therapy toxicities. JCO Oncology Practice, 19(3), e407–e416. https://doi.org/10.1200/OP.22.00501
Szoch, S., Boord, C., Duffy, A., & Patzke, C. (2018). Addressing administration challenges associated with blinatumomab infusions: A multidisciplinary approach. Journal of Infusion Nursing, 41(4), 241–246. https://doi.org/10.1097/NAN.0000000000000283
Tedesco, V. E., & Mohan, C. (2021). Biomarkers for predicting cytokine release syndrome following CD19-targeted CAR T cell therapy. Journal of Immunology, 206(7), 1561–1568. https://doi.org/10.4049/jimmunol.2001249
Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D.,…Lugtenburg, P. J. (2023). Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. Journal of Clinical Oncology, 41(12), 2238–2247. https://doi.org/10.1200/JCO.22.01725
van de Donk, N. W. C. J., & Zweegman, S. (2023). T-cell-engaging bispecific antibodies in cancer. Lancet, 402(10396), 142–158. https://doi.org/10.1016/S0140-6736(23)00521-4
Varshavsky-Yanovsky, N. A., Styler, M., Khanal, R., Abdelmessieh, P., & Fung, H. (2023). P940: An outpatient model for teclistamab step-up dosing administration – Initial experiences at Fox Chase Cancer Center BMT program. HemaSphere, 7(S3). https://journals.lww.com/hemasphere/fulltext/2023/08003/p940__an_outpatient_model_for_teclistamab_step_up.840.aspx
Wang, Z., & Han, W. (2018). Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomarker Research, 6, 4. https://doi.org/10.1186/s40364-018-0116-0
Winterling, J., Kisch, A., Alvariza, A., Årestedt, K., & Bergkvist, K. (2022). Preparedness for family caregiving prior to allogeneic hematopoietic stem cell transplantation. Palliative & Supportive Care, 20(4), 519–526. https://doi.org/10.1017/S1478951521001346
Yáñez, L., Sánchez-Escamilla, M., & Perales, M.-A. (2019). CAR T cell toxicity: Current management and future directions. HemaSphere, 3(2), e186. https://doi.org/10.1097/HS9.0000000000000186
